SI3621960T1 - Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji - Google Patents

Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji

Info

Publication number
SI3621960T1
SI3621960T1 SI201830426T SI201830426T SI3621960T1 SI 3621960 T1 SI3621960 T1 SI 3621960T1 SI 201830426 T SI201830426 T SI 201830426T SI 201830426 T SI201830426 T SI 201830426T SI 3621960 T1 SI3621960 T1 SI 3621960T1
Authority
SI
Slovenia
Prior art keywords
thienopyridines
benzothiophenes
useful
irak4 inhibitors
irak4
Prior art date
Application number
SI201830426T
Other languages
English (en)
Inventor
Saleem Ahmad
Ling Li
Lidet A. Negash
John Hynes
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI3621960T1 publication Critical patent/SI3621960T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201830426T 2017-05-11 2018-05-10 Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji SI3621960T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504956P 2017-05-11 2017-05-11
EP18727589.6A EP3621960B1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors
PCT/US2018/031945 WO2018209012A1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors

Publications (1)

Publication Number Publication Date
SI3621960T1 true SI3621960T1 (sl) 2021-11-30

Family

ID=62245511

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830426T SI3621960T1 (sl) 2017-05-11 2018-05-10 Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji

Country Status (27)

Country Link
US (1) US10829496B2 (sl)
EP (1) EP3621960B1 (sl)
JP (1) JP7154229B2 (sl)
KR (1) KR102604900B1 (sl)
CN (1) CN110612298B (sl)
AR (1) AR111689A1 (sl)
AU (1) AU2018265130B2 (sl)
BR (1) BR112019023290A2 (sl)
CA (1) CA3062602A1 (sl)
CL (1) CL2019003198A1 (sl)
CO (1) CO2019012494A2 (sl)
CY (1) CY1124552T1 (sl)
DK (1) DK3621960T3 (sl)
EA (1) EA039189B1 (sl)
ES (1) ES2889926T3 (sl)
HR (1) HRP20211583T1 (sl)
HU (1) HUE056493T2 (sl)
IL (1) IL270494B (sl)
LT (1) LT3621960T (sl)
MX (1) MX2019012929A (sl)
PE (1) PE20191817A1 (sl)
PL (1) PL3621960T3 (sl)
PT (1) PT3621960T (sl)
RS (1) RS62430B1 (sl)
SI (1) SI3621960T1 (sl)
TW (1) TW201900640A (sl)
WO (1) WO2018209012A1 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein compounds and their uses
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
AU2018396142A1 (en) 2017-12-26 2020-07-16 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
WO2020113233A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
CN114174304B (zh) * 2019-07-23 2024-05-17 百时美施贵宝公司 可用作irak4抑制剂的噻吩并吡啶基化合物和噻唑并吡啶基化合物
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
AU2020407200A1 (en) 2019-12-17 2022-07-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
ATE432929T1 (de) 2001-06-15 2009-06-15 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
CN1665789A (zh) 2002-06-28 2005-09-07 山之内制药株式会社 二氨基嘧啶酰胺衍生物
CA2512646A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CN1820001A (zh) 2003-07-10 2006-08-16 神经能质公司 经取代的杂环二芳基胺类似物
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
CN101171052A (zh) 2005-03-09 2008-04-30 先灵公司 抑制ksp驱动蛋白活性的化合物
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1989211A2 (en) 2006-01-30 2008-11-12 Array Biopharma, Inc. Heterobicyclic thiophene compounds for the treatment of cancer
CN101679376A (zh) 2007-06-08 2010-03-24 拜尔农科股份有限公司 杀真菌剂杂环-嘧啶基-氨基衍生物
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JP5254693B2 (ja) 2008-07-30 2013-08-07 三菱重工業株式会社 Ｎｉ基合金用溶接材料
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
US8575153B2 (en) 2008-11-28 2013-11-05 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP2012529535A (ja) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
NZ598455A (en) 2009-09-03 2014-03-28 Allergan Inc Compounds as tyrosine kinase modulators
EP2493863B1 (en) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
WO2011093501A1 (ja) 2010-02-01 2011-08-04 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
US20140142094A1 (en) 2011-04-29 2014-05-22 Icahn School Of Medicine At Mount Sinai Kinase inhibitors
US8987311B2 (en) 2012-01-13 2015-03-24 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
ES2575604T3 (es) 2012-01-13 2016-06-29 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa
ES2686500T3 (es) 2012-01-13 2018-10-18 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas
US9546153B2 (en) 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
EA024940B1 (ru) 2012-11-08 2016-11-30 Бристол-Майерс Сквибб Компани Гетероарилзамещённые пиридильные соединения, применимые в качестве модуляторов киназ
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
US10040802B2 (en) * 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of IRAK4 activity
EP3268367B8 (en) * 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
WO2016210034A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
CN108026099B (zh) 2015-06-24 2020-07-10 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
EP3858825A1 (en) * 2015-08-27 2021-08-04 Pfizer Inc. Bicyclic-fused heteroaryl compounds as irak4 modulators

Also Published As

Publication number Publication date
DK3621960T3 (da) 2021-09-27
CN110612298A (zh) 2019-12-24
JP2020519596A (ja) 2020-07-02
CN110612298B (zh) 2023-05-05
BR112019023290A2 (pt) 2020-06-16
HRP20211583T1 (hr) 2022-01-07
AU2018265130B2 (en) 2022-03-24
ES2889926T3 (es) 2022-01-14
US20200062777A1 (en) 2020-02-27
MX2019012929A (es) 2020-01-14
TW201900640A (zh) 2019-01-01
US10829496B2 (en) 2020-11-10
KR102604900B1 (ko) 2023-11-21
PT3621960T (pt) 2021-09-16
RS62430B1 (sr) 2021-11-30
EP3621960B1 (en) 2021-08-04
KR20200004871A (ko) 2020-01-14
CY1124552T1 (el) 2022-07-22
WO2018209012A1 (en) 2018-11-15
CL2019003198A1 (es) 2020-03-20
EA201992674A1 (ru) 2020-04-06
CO2019012494A2 (es) 2020-01-17
PL3621960T3 (pl) 2021-11-08
JP7154229B2 (ja) 2022-10-17
LT3621960T (lt) 2021-10-11
IL270494B (en) 2022-04-01
EA039189B1 (ru) 2021-12-15
PE20191817A1 (es) 2019-12-27
AR111689A1 (es) 2019-08-07
CA3062602A1 (en) 2018-11-15
HUE056493T2 (hu) 2022-02-28
AU2018265130A1 (en) 2020-01-02
EP3621960A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
IL270494B (en) Thienopyridines and benzothiophenase are useful as irak4 inhibitors
PL3718370T3 (pl) Sposoby i powiązane urządzenia służące do realizacji funkcji multi-connectivity
IL269196A (en) New inhibitors
IL269711B (en) ask1 inhibitory compounds and uses thereof
EP3268003A4 (en) Thienopyrazine inhibitors of irak4 activity
EP3283488A4 (en) Heterocycles useful as ido and tdo inhibitors
FI3672976T3 (fi) Bcl-2-inhibiittoreita
SG11202003790PA (en) Composition and method
EP3336091A4 (en) IRAQ4 INHIBITOR AND ITS USE
PL3621694T3 (pl) Inhibitory lrrc33 i ich zastosowanie
IL274425A (en) Pyrrolopyrazine derivatives as alpha five integrin inhibitors
EP3336090A4 (en) INHIBITOR OF IRAQ4 AND ITS USE
ZA201907136B (en) Ip6k inhibitors
HUE052351T2 (hu) NAP I-IIB inhibitor kondenzált tiofén-származékok
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
PL3474883T3 (pl) Inhibitory dopełniacza i ich zastosowania
IL275935A (en) Its use and its derivative
IL274550A (en) Dopamine-B-hydroxylase inhibitors
EP3704104A4 (en) IRAK4 INHIBITORS AND THEIR USES
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
IL281216A (en) Inhibitors of glutaminyl cyclase
ZA201904187B (en) Method and composition
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201714238D0 (en) Composition and method